PDCD1 and colorectal carcinoma: Liu et al. confirmed that the inhibition of PCSK9 could enhance the synergistic antitumor effect of programmed cell death-1 (PD-1) inhibitors (immune checkpoint inhibitors [ICIs]) in colorectal cancer (CRC).